Exploring how magnetic therapy can help improve attention and overall symptoms in ADHD

EFFICACY AND SAFETY OF ACCELERATED iTBS AS AN ADD ON THERAPY AND ITS IMPACT ON COGNITIVE FUNCTIONS IN ADOLESCENTS WITH ADHD - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/104548

Enrollment

Registered

2026-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F902- Attention-deficit hyperactivity disorder, combined type

Interventions

Intervention1: Active Accelerated intermittent theta burst stimulation: Patient will receive accelerated iTBS at 100 percent of RMT Patients receiving active accelerated iTBS will get 5 sessions at in

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) according to DSM-5 criteria. Stable dosages of atomoxetine (or other non-stimulant medication) for at least 4 weeks prior to study entry. Willingness and ability to comply with study procedures, including followup visits for TMS sessions. Written informed assent from the adolescent and informed consent from a parent/legal guardian.

Exclusion criteria

Exclusion criteria: Presence of other Neurodevelopmental disorders, any other psychiatric condition. Any neurological disorder like epilepsy, Cerebral Palsy, movement disorders. Intellectual disability as assessed clinically. Any medical/ psychiatric condition requiring priority management. Use of stimulant medication, benzodiazepine, AED within 4 weeks Any cognitive/structured behavior therapy/ neurofeedback sessions within 3 months. Presence of metal implants in the head/brain, pacemakers, or any other contraindications to TMS

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy and safety of accelerated Intermittent theta burst stimulation (iTBS) in Adolescents with ADHD as add on therapyTimepoint: Baseline 2 week 4 week	—

Secondary

Measure	Time frame
To compare the ADHD symptom severity and cognitive task performance among adolescents with ADHD receiving non stimulant pharmacotherapy with add on accelerated iTBS with those receiving non stimulant pharmacotherapy alone.Timepoint: Baseline 2 weeks 4 weeks;To compare the subjective well being of adolescents with ADHD receiving non stimulant pharmacotherapy with add on accelerated iTBS with those receiving non stimulant pharmacotherapy alone.Timepoint: Baseline 2 weeks 4 weeks	—

Measure

Time frame

To compare the ADHD symptom severity and cognitive task performance among adolescents with ADHD receiving non stimulant pharmacotherapy with add on accelerated iTBS with those receiving non stimulant pharmacotherapy alone.Timepoint: Baseline 2 weeks 4 weeks;To compare the subjective well being of adolescents with ADHD receiving non stimulant pharmacotherapy with add on accelerated iTBS with those receiving non stimulant pharmacotherapy alone.Timepoint: Baseline 2 weeks 4 weeks

—

Countries

India

Contacts

Public ContactDr Amit Arya

King George Medical University

amitarya@kgmcindia.edu9415766243

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026